Global Hemophilia Market: Industry Analysis & Outlook (2018-2022)
The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion of the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes abnormal bleeding with poor clotting. It is classified into hemophilia A, hemophilia B, hemophilia C, and hemophilia with inhibitors.
Treatment for hemophilia is done via replacement therapy, prophylactic therapy, on-demand therapy, gene therapy and many others. Gene therapy is being regarded as an attractive option for treatment of hemophilia. By the year 2030, the pharmaceutical companies are expected to launch their gene therapy treatment for hemophilia, and this might affect the market dynamics at large.
The growth factors of the hemophilia market include increased focus on prophylactic treatment, growing market for FVIII, increasing diagnosis rate, and increasing healthcare expenditure. Major trends of the market include development of novel hemophilia treatment, shifting to extended half-life therapies and growing popularity of gene therapy. Further, growth prospects are hindered by high cost of therapy and consumer’s reluctance in switching to new therapy options.
The report offers an in-depth analysis of the global hemophilia market. It covers the global as well as regional aspect of the market. The top notch players in the market exhibit a very close competitive landscape. The report profiles Pfizer Inc., Bayer Group, Shire PLC, and Novo Nordisk.